Sign In
Buy PGEN
$3.81
-0.0500 (-1.30%)
At Close: Jun 03, 2026
Precigen: This Billion-Dollar Approval Is Still Undervalued
03:15pm, Friday, 15'th Aug 2025
PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, t
Why Is Precigen Stock Surging On Friday?
09:48am, Friday, 15'th Aug 2025
On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).
US FDA approves Precigen's immunotherapy for rare respiratory disease
07:18am, Friday, 15'th Aug 2025
The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with RRP PAPZIMEOS received full approval from the FD
Precigen: August Is Pivotal For This Biotech Innovator
05:58pm, Monday, 07'th Jul 2025
Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Rec
Precigen Reports First Quarter 2025 Financial Results and Business Updates
04:05pm, Wednesday, 14'th May 2025
PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company's BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA targ
Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
08:05am, Wednesday, 16'th Apr 2025
– International event will raise awareness and bring together RRP patients , caregivers, and the healthcare community supporting them – – Recurrent respiratory papillomatosis is a rare, debilita
Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript
07:47pm, Wednesday, 19'th Mar 2025
Precigen, Inc. (NASDAQ:PGEN ) Q4 2024 Earnings Conference Call March 19, 2025 4:30 PM ET Company Participants Steven Harasym - IR Helen Sabzevari - President and CEO Rutul Shah - COO Phil Tennant - CC
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
07:25pm, Wednesday, 19'th Mar 2025
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.09 per share a year ago.
Precigen Reports Full Year 2024 Financial Results and Business Updates
04:05pm, Wednesday, 19'th Mar 2025
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025 Results from pivot
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th
08:05am, Thursday, 13'th Mar 2025
GERMANTOWN, Md. , March 13, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement
08:56am, Friday, 28'th Feb 2025
BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge be
– Priority review reduces the BLA review timeline to 6-months and is granted to therapies that, if approved, would provide significant improvements in the treatment, diagnosis or prevention of serio
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?
10:55am, Thursday, 20'th Feb 2025
Precigen, Inc. (PGEN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PGEN's 50-day simple moving average crossed above its 2
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Monday, 13'th Jan 2025
– PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treat
